55 results on '"Aktas Samur A"'
Search Results
2. Abstract P37: Decoding Cancer Dependency and Molecular Pathways of Long Noncoding RNAs with a Novel CRISPR-Cas13d Platform
3. P-194 Non-coding RNA LINC01410 interacts with the minichromosome maintenance (MCM) complex and is a dependency in multiple myeloma
4. Monoallelic Deletion of BCMA is a frequent feature in multiple myeloma
5. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma
6. A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth
7. In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors
8. Long Noncoding RNA LINC01410 Interacts with the Minichromosome Maintenance (MCM) Complex to Promote Tumor Cell Growth in Multiple Myeloma
9. In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis
10. Somatic Changes Prior to the Development of Hyperdiploidy Expose Mutation Accumulation Rate and Activated Processes in Multiple Myeloma
11. Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors
12. Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma
13. Long Noncoding RNA RROL Provides Chromatin Scaffold for MYC-WDR82 Interaction to Impact Lipid Metabolism and Tumor Cell Growth in Multiple Myeloma
14. Identifying Long Noncoding RNA Dependencies Using CRISPR Interference (CRISPRi)-Based Platform in Multiple Myeloma
15. Decreasing Costs and Clinic Wait Time While Maintaining Safety for Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) for Multiple Myeloma
16. Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma
17. Dysfunctional HDAC8 Impacts Genomic Integrity and Is a Novel Therapeutic Target in Multiple Myeloma
18. Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma
19. B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication
20. 16p Deletion Involving BCMA Locus Is Frequent and Predominantly Observed with del17p
21. Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells
22. OAB-022: Monoallelic deletion of BCMA locus is a frequent feature in MM and is associated with increased genomic loss
23. OAB-009: Genome-wide CRISPR interference screen identifies RNA Regulator of Lipogenesis (RROL) as a leading LncRNA dependency in Multiple Myeloma
24. OAB-043: Progression and probability of progression are driven by different genomic features in precursor conditions in myeloma
25. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
26. Prevention of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Therapy: Real-World Examination of the Impede Study
27. Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma
28. RNA Regulator of Lipogenesis (RROL) Is a Novel Lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma
29. High Throughput Genomic Analysis Identifies Low-Risk Smoldering Multiple Myeloma
30. High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma
31. Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models
32. Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma
33. Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD)
34. Atpase Family AAA Domain-Containing Protein 2 (ATAD2) As a Novel Target in Multiple Myeloma
35. Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature
36. Exploring POU2AF1 (BOB-1) Dependency and Transcription Addiction in Multiple Myeloma
37. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group
38. Genome Wide Transcriptomic Analysis Identifies Dysregulated Splicing Factor Profile with Molecular and Functional Role in Multiple Myeloma
39. Targeting Myeloma Cell Metabolism Via Disruption of the Lnc-17-92 Transcriptional Program: Druggable New Vulnerability in Multiple Myeloma
40. The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma
41. Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study
42. Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma
43. The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche
44. S119 THE ROLE OF RECURRENT SOMATIC ALTERATIONS IN THE NON-CODING GENOME WITH FUNCTIONAL IMPLICATIONS IN MM
45. S120 CHRONOLOGY OF COPY NUMBER ALTERATIONS FROM PRECURSORS TO MULTIPLE MYELOMA: WHAT COMES FIRST?
46. Deciphering the chronology of copy number alterations in Multiple Myeloma
47. Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma
48. Deciphering the Chronology of Copy Number Alterations in Multiple Myeloma (MM): What Comes First?
49. Dysregulation of Splicing in Multiple Myeloma: The Splicing Factor SRSF1 Supports MM Cell Proliferation Via Splicing Control
50. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.